Clovis Oncology, Inc. (NASDAQ:CLVS) has scheduled a conference call for 5th November 2020 at 8:30 AM Eastern Time to announce its 3Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.clovisoncology.com
Earnings Expectation
Clovis Oncology, Inc. is expected to report third quarter earnings results, before market open, on Thursday 5th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.99 per share from revenue of $ 42.64 million. Looking ahead, the full year loss are expected at $ 4.32 per share on the revenues of $ 172.30 million.
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors.
